0 Shares 17 Views

Puma Biotech (PBYI) Down More Than 40% in 90 Days: Here’s Why – Zacks.com

January 11, 2019
17 Views

Puma Biotech (PBYI) Down More Than 40% in 90 Days: Here’s Why Zacks.com

Puma Biotech’s (PBYI) only marketed drug, Nerlynx, is suffering low sales due to higher patient discontinuations.

View More

You may be interested

Studie: Nachfrage nach E-Autos steigt langsam an – BILD
Markets and Investment
14 views
Markets and Investment
14 views

Studie: Nachfrage nach E-Autos steigt langsam an – BILD

webmaster - January 17, 2019

Studie: Nachfrage nach E-Autos steigt langsam an BILDEs geht voran mit der Elektro-Mobilität: Die Nachfrage nach Elektroautos und Plug-Ins ist weltweit im vergangenen Jahr gestiegen. Vorreiter ist…

Voltalia: lancement d’un projet solaire-stockage en Guyane – EasyBourse.com
Bourses
13 views
Bourses
13 views

Voltalia: lancement d’un projet solaire-stockage en Guyane – EasyBourse.com

webmaster - January 17, 2019

Voltalia: lancement d'un projet solaire-stockage en Guyane EasyBourse.com(CercleFinance.com) - Voltalia annonce le lancement de la construction du projet Savane des Pères en Guyane française, une centrale solaire…

Wipro Q3 results on Friday; will IT firm meet its guidance?
Trading and broking
12 views
Trading and broking
12 views

Wipro Q3 results on Friday; will IT firm meet its guidance?

webmaster - January 17, 2019

Margins are expected to expand 20-50 basis points sequentially.

Most from this category